Viruses lacking epithelial cell receptor entry

Patent metadata

Field	Value
Publication number	US-9434768-B2
Application number	US-201414249821-A
Country	US
Kind code	B2
Filing date	Apr 10, 2014
Priority date	Mar 21, 2008
Publication date	Sep 6, 2016
Grant date	Sep 6, 2016

Abstract

The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed.

First claim

What is claimed is:

1. An isolated nucleic acid molecule, wherein said nucleic acid molecule encodes a polypeptide comprising a hemagglutinin (H) polypeptide amino acid sequence that aligns with and has at least 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 1, wherein said H amino acid sequence comprises an amino acid other than leucine at the position aligning with position 482 of said amino acid sequence, wherein said amino acid other than leucine is serine.

2. The isolated nucleic acid of claim 1 , wherein said H polypeptide amino acid sequence further comprises an amino acid other than proline at the position aligning with position 497 of said amino acid sequence or an amino acid other than tyrosine at the position aligning with position 543 of said amino acid sequence.

3. The isolated nucleic acid of claim 2 , wherein said H polypeptide amino acid sequence further comprises a serine at the position aligning with position 497 of said amino acid sequence.

4. The isolated nucleic acid of claim 2 , wherein said H polypeptide amino acid sequence further comprises an alanine at the position aligning with position 543 of said amino acid sequence.

5. The isolated nucleic acid of claim 2 , wherein said H polypeptide amino acid sequence further comprises a serine at the position aligning with position 497 of said amino acid sequence and an alanine at the position aligning with position 543 of said amino acid sequence.

6. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid molecule further encodes an F polypeptide.

7. A cell comprising the isolated nucleic acid molecule of claim 1 .

8. The cell of claim 7 , wherein said cell is a cell line or a primary cell, wherein said cell line is selected from the group consisting of a Vero cell line, a Vero/hSLAM cell line, and a Jurkat cell line, wherein said primary cell is selected from the group consisting of B lymphocytes, T lymphocytes, dendritic cells, macrophages, and cells from resected primary tumors.

9. A virus comprising the isolated nucleic acid molecule of claim 1 .

10. The virus of claim 9 , wherein said virus is selected from the group consisting of a measles virus, a canine distemper virus, and a rinderpest virus.

11. The virus of claim 10 , wherein said virus is a measles virus.

12. The virus of claim 11 , wherein said measles virus is a vaccine strain.

Assignees

• Mayo Foundation

Inventors

• Cattaneo Roberto
• Leonard Vincent H J

Classifications

• A61K39/165

  Mumps or measles virus · CPC title

• C12N15/09

  Recombinant DNA-technology · CPC title

• C12N2760/18422

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61K31/7105

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• C12N2760/18434

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title